Literature DB >> 9603118

Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.

R J van Suylen1, J F Smits, M J Daemen.   

Abstract

In the present study we analyzed structural characteristics of muscular pulmonary arteries and arterioles in two classic models of pulmonary hypertension, the rat hypoxia and monocrotaline models. We hypothesized that an increase in medial cross-sectional area would result in reduction of the lumen area and that these parameters would correlate with the increase in pulmonary artery pressure (PAP). Four weeks after a single injection of monocrotaline (MCT) or after 4 wk of hypoxic exposure the rats were killed. Both MCT and chronic hypoxia induced right ventricular hypertrophy. In separate groups of rats both MCT and chronic hypoxia increased PAP. MCT increased the media cross-sectional area of pulmonary arteries with an external diameter between 30-100 microm and 101-200 microm and reduced the lumen area of pulmonary arteries with an external diameter between 101-200 microm. Chronic hypoxia only slightly increased the media cross-sectional area without a change of the lumen area. Both MCT and hypoxia increased the percentage of partly muscularized and muscularized arterioles. The angiotensin-converting enzyme (ACE) inhibitor captopril (0.5 mg/kg/h) had no effect on MCT-induced pulmonary hypertension, right ventricular hypertrophy, and pulmonary artery remodeling. In chronic hypoxic rats it prevented an increase in medial cross-sectional area of pulmonary arteries with an external diameter between 30-100 microm and attenuated the increase in the percentage of muscularized arterioles, without any effect on the PAP. We conclude that MCT, in contrast to chronic hypoxia, induces structural changes of muscular pulmonary arteries with an external diameter between 101-200 microm which may contribute to an increased PAP and right ventricular hypertrophy. These data also suggest that angiotensin II plays a pivotal role in remodeling of pulmonary arteries in hypoxia but not in MCT-induced pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603118     DOI: 10.1164/ajrccm.157.5.9709050

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology.

Authors:  Norah Alruwaili; Sharath Kandhi; Dong Sun; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2018-12-21       Impact factor: 8.401

3.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  Reduction of reactive oxygen species prevents hypoxia-induced CREB depletion in pulmonary artery smooth muscle cells.

Authors:  Dwight J Klemm; Susan M Majka; Joseph T Crossno; John C Psilas; Jane E B Reusch; Chrystelle V Garat
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 5.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

6.  Egr-1 expression during neointimal development in flow-associated pulmonary hypertension.

Authors:  Michael G Dickinson; Beatrijs Bartelds; Grietje Molema; Marinus A Borgdorff; Bibiche Boersma; Janny Takens; Michel Weij; Pieter Wichers; Hannie Sietsma; Rolf M F Berger
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

7.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.

Authors:  Christopher C Sullivan; Lingling Du; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

8.  Captopril improves postresuscitation hemodynamics protective against pulmonary embolism by activating the ACE2/Ang-(1-7)/Mas axis.

Authors:  Hong-Li Xiao; Chun-Sheng Li; Lian-Xing Zhao; Jun Yang; Nan Tong; Le An; Qi-Tong Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-22       Impact factor: 3.000

9.  Mitigation of radiation induced pulmonary vascular injury by delayed treatment with captopril.

Authors:  Robert C Molthen; Qingping Wu; Brian L Fish; John E Moulder; Elizabeth R Jacobs; Meetha M Medhora
Journal:  Respirology       Date:  2012-11       Impact factor: 6.424

10.  Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Ivan F McMurtry; Masahiko Oka; Eva Nozik-Grayck; Masanobu Komatsu; Fakhrul Ahsan
Journal:  J Control Release       Date:  2013-01-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.